The clinical significance of adiponectimics in formation of affected target-organs during the metabolic syndrome associated with nonalcoholic fatty liver disease
Abstract
The goal of this research is to estimate the clinical significance of adiponectimics in formation of affected target-organs during the metabolic syndrome associated with nonalcoholic fatty liver disease.
About the Authors
E. A. Saginova
First MSMU named after I. M. Sechenov
Russian Federation
Russian Federation
PhD, assistant of the chair of therapy and occupational diseases
M. M. Severova
First MSMU named after I. M. Sechenov
Russian Federation
Russian Federation
post-graduate student of the chair of therapy and occupational diseases
M. G. Gallyamov
Moscow state university named after M. V. Lomonosov
Russian Federation
Russian Federation
post-graduate student of the chair of internal medicine
N. V. Ermakov
Moscow research institute of medical ecology
Russian Federation
Russian Federation
PhD, head of developing the diagnostic test systems laboratory
A. V. Rodina
Moscow research institute of medical ecology; First MSMU named
after I. M. Sechenov
Russian Federation
Russian Federation
PhD, senior research fellow of the Moscow research institute of medical ecology; assistant of the chair of biochemistry of the First MSMU named after I. M. Sechenov
V. V. Fomin
First MSMU named after I. M. Sechenov
Russian Federation
Russian Federation
MD, prof. of the chair of therapy and occupational diseases, dean of the faculty of pre-university education
N. A. Mukhin
First MSMU named after I. M. Sechenov
Russian Federation
Russian Federation
MD, corresp. member of RAMS, prof., head of the chair of therapy and occupational diseases, director of the clinic of nephrology, medical and occupational diseases named after E. M. Tareev of the university hospital № 3
References
1. Ritchie S.A., Connell J.M. The link between abdominal obesity, metabolic syndrome and cardiovascular disease. Nutr. Metab. Cardiovasc. Dis. 2007; 17 (4): 319–326.
2. Antuna-Puente B., Feve B., Fellahi S. Adipokines: the missing link between insulin resistance and obesity. Diabetes Metab. 2008; 34 (1): 2–11.
3. Anubhuti, Arora S. Leptin and its metabolic interactions: an update. Diabetes Obes. Metab. 2008; 10 (11): 973–993.
4. Han S.H., Sakuma I., Shin E.K., Koh K.K. Antiatherosclerotic and anti-insulin resistance effects of adiponectin: basic and clinical studies. Prog Cardiovasc Dis. 2009; 52 (2): 126–140.
5. Han S.H., Quon M.J., Kim J.A., Koh K.K. Adiponectin and cardiovascular disease: response to therapeutic interventions. J. Am. Coll. Cardiol. 2007; 49 (5): 531–538.
6. Диагностика и лечение метаболического синдрома: Российские рекомендации / Комитет экспертов ВНОК. М., 2009.
7. Диагностика и лечение артериальной гипертензии: Рекомендации Рос. мед. общ-ва по артериальной гипертонии и Всерос. науч. общ-ва кардиологов / Комитет экспертов РМОАГ/ВНОК // Системные гипертензии. 2010. № 3. С. 5–26.
8. Huang Y., Chen Y., Xu M. et al. Low-grade albuminuria is associated with carotid intima-media thickness in Chinese type 2 diabetic patients. J. Clin. Endocrinol. Metab. 2010; 95 (11): 5122–5128.
9. Wachtell K., Olsen M.H., Dahlöf B. et al. Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. J. Hypertens. 2002; 20 (3): 405–412.
10. Yasui K., Sumida Y., Mori Y. et al. Nonalcoholic steatohepatitis and increased risk of chronic kidney disease. Metabolism. 2010 Sep 1 [Epub ahead of print].
11. Chang Y., Ryu S., Sung E. et al. Nonalcoholic fatty liver disease predicts chronic kidney disease in nonhypertensive and nondiabetic Korean men. Metabolism. 2008; 57 (4): 569–576.
12. Targher G., Chonchol M., Bertolini L. et al. Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease. J. Am. Soc. Nephrol. 2008; 19 (8): 1564–1570.
13. Goland S., Shimoni S., Zornitzki T. et al. Cardiac abnormalities as a new manifestation of nonalcoholic fatty liver disease: echocardiographic and tissue Doppler imaging assessment. J. Clin. Gastroenterol. 2006; 40 (10): 949–955.
14. Salvi P., Ruffini R., Agnoletti D. et al. Increased arterial stiff-ness in nonalcoholic fatty liver disease: the Cardio-GOOSE study. J. Hypertens. 2010; 28 (8): 1699–1707.
15. Kim H.C., Kim D.J., Huh K.B. Association between nonalcoholic fatty liver disease and carotid intima-media thickness according to the presence of metabolic syndrome. Atherosclerosis. 2009; 204 (2): 521–525.
16. Wolf G, Ziyadeh FN. Leptin and renal fibrosis. Contrib Nephrol. 2006; 151:175-183.
17. Мухин Н.А., Фомин В.В., Сагинова Е.А. и др. Эндотелиальная дисфункция и поражение почек при ожирении // Вестник РАМН. 2006. № 12: С. 25–31.
18. Oda N., Imamura S., Fujita T. et al. The ratio of leptin to adiponectin can be used as an index of insulin resistance. Metabolism. 2008; 57 (2): 268–273.
19. Thorand B., Zierer A., Baumert J. et al. Associations between leptin and the leptin / adiponectin ratio and incident Type 2 diabetes in middle-aged men and women: results from the MONICA / KORA Augsburg study 1984–2002. Diabet. Med. 2010 Sep; 27(9): 1004–1011.
20. Saarikoski L.A., Huupponen R.K., Viikari JS. et al. Adiponectin is related with carotid artery intima-media thickness and brachial flow-mediated dilatation in young adults – the Cardiovascular Risk in Young Finns Study. Ann. Med. 2010; 42 (8): 603–611.
21. Huang S.S., Huang P.H., Chen Y.H. et al. Association of adiponectin with future cardiovascular events in patients after acute myocardial infarction. J. Atheroscler. Thromb. 2010; 17 (3): 295–303.
22. Norata G.D., Raselli S., Grigore L. et al. Leptin:adiponectin ratio is an independent predictor of intima media thickness of the common carotid artery. Stroke. 2007; 38(10): 2844-2846
23. Cesari M., Pessina A.C., Zanchetta M. et al. Low plasma adiponectin is associated with coronary artery disease but not with hypertension in high-risk nondiabetic patients. J. Intern. Med. 2006; 260(5): 474-483
24. Hashimoto N., Kanda J., Nakamura T. et al. Association of hypoadiponectinemia in men with early onset of coronary heart disease and multiple coronary artery stenoses. Metabolism. 2006; 55(12): 1653-1657
25. Uribe M., Zamora-Valdés D., Moreno-Portillo M. et al. Hepatic expression of ghrelin and adiponectin and their receptors in patients with nonalcoholic fatty liver disease. Ann. Hepatol. 2008; 7 (1): 67–71.
26. Hindle A.K., Edwards C., Mendonsa A. et al. Adiponectin but not leptin is involved in early hepatic disease in morbidly obese patients. Surg. Endosc. 2010; 24 (7): 1547– 1551.
27. Ma H., Gomez V., Lu L. et al. Expression of adiponectin and its receptors in livers of morbidly obese patients with nonalcoholic fatty liver disease. J. Gastroenterol. Hepatol. 2009; 24 (2): 233–237.
28. Jiang L.L., Li L., Hong X.F. et al. Patients with nonalcoholic fatty liver disease display increased serum resistin levels and decreased adiponectin levels. Eur. J. Gastroenterol. Hepatol. 2009; 21 (6): 662–666.
Review
Views: 30
Email this article 